Stephen KeithSenior Medical Director, Medical and Scientific Management at Syneos Health, USA
Stephen joined Syneos Health, an integrated end-to-end clinical and commercial solution company for biopharmaceutical development, as a Senior Medical Director, Medical Management and Scientific Services, in 2018. He completed his undergraduate studies at Amherst College, and received the M.D. degree from the University of Illinois. Stephen completed a three-year residency in Pediatrics at the University of California, Los Angeles, Center for the Health Sciences, following which he was a Robert Wood Johnson Foundation Clinical Scholar at UCLA, during which time he
received a Masters in Science in Public Health from UCLA. Subsequently he served on the faculty of the Charles Drew Medical School and the UCLA School of Medicine in the Department of Pediatrics. Stephen is a Fellow of the Academy of Pediatrics and a Diplomate of the American
Board of Pediatrics. Since joining Syneos Health, Dr. Keith has participated as a presenter in two 2020 BAM Camp Summer Momentum Virtual Meeting Sessions, as well as a conversation with former FDA Commisssioner Peggy Hamburg, concerning the imperative to increase diversity in
clinical trials. He is also working to establish a clinical investigator training program for potential minority investigators as part of the effort to increase diversity in clinical trials.
During his more than 25 year career in the pharmaceutical and biotechnology industries, Dr. Keith has worked in various capacities with companies that have developed protein conjugate vaccines to prevent disease caused by Haemophilus influenza Type B, meningococcal, pneumococcal, and
Group B Streptoccocal bacterial organisms, along with diphtheria, tetanus, pertussis, and inactivated polio vaccines. Over the past 2 years at Syneos Health, Stephen has served as the lead Medical Director on a Phase II study of a therapeutic for adults with myasthenia gravis, a Phase II study of a therapeutic for children with Tourette Syndrome, a Phase II/III study of a seasonal influenza vaccine in individuals >65 years of age, a Phase II gene therapy study for boys with Duchenne Muscular Dystrophy, a Phase II study of a therapeutic in pediatric MPS IIIA, a Phase II study of an antibiotic in children with gram negative infections, a Phase II study of an antiviral for immunocompromised children with adenovirus infection, and a Phase III study of a therapeutic in children with Spinal Muscular Atropy. He will soon initiate another Phase II study of a therapeutic for adults with myasthenia gravis.
Previously, he served as Chief Executive Officer of Vivacelle Bio, President and Chief Operating Officer of Panacea Pharmaceuticals, General Partner with Emerging Technology Partners, an earlystage life sciences venture capital firm, President and Chief Operating Officer of Antex Biologics, and Vice President, Marketing and Sales, at North American Vaccine. Earlier in his career Stephen held various positions at Merck & Co. Prior to entering the pharmaceutical industry, he served as a Health Policy Advisor to the U.S. Senate Committee on Labor and Human Resources, under Senator Edward M. Kennedy. Stephen serves on the Board of Directors of Evanston Technology Partners, National Medical Fellowships, and MATTER, a global healthcare startup incubator, community nexus and corporate innovation accelerator headquartered in Chicago. He is based is based in Chicago IL, is married to Helene Gayle, MD, MPH, and has three adult children.